Understanding species-specific drug metabolism is essential for interpreting in vivo data and selecting appropriate animal models in DMPK studies. This whitepaper examines how CYP inhibition influences antipyrine metabolism in cats and guinea pigs, highlighting differences in metabolic profiles between species and the impact of ABT treatment. The findings provide a clearer perspective on the role of oxidative metabolism in drug exposure and offer useful considerations for cross-species metabolism assessment and animal model selection.

• Cross-species perspective: Compares antipyrine metabolism across cats and guinea pigs to reveal species-dependent differences
• CYP inhibition insights: Examines how ABT-mediated CYP inhibition alters drug metabolism and exposure
• Metabolite profiling: Provides a comprehensive view of metabolic changes across species and treatment conditions
• DMPK relevance: Supports more informed interpretation of in vivo metabolism data and animal model selection

Download the full whitepaper to explore how cross-species metabolite profiling and CYP inhibition studies can provide valuable insights for DMPK research.